-
Results fourth quarter and full year 201228 Feb 2013 -
Presentation of Cevira® Phase 2b Results05 Dec 2012
-
PHOTOCURE ANNOUNCES POSITIVE RESULTS OF CEVIRA® STUDYRESULTS DEMONSTRATE SIGNIFICANT EFFICACY IN TREATMENT OF LESIONS AND ONCOGENIC HUMAN PAPILLOMA VIRUS IN PATIENTS WITH PRECANCEROUS LESIONS OF THE CERVIX05 Dec 2012
-
Results third quarter and first nine months 2012Oslo, Norway, 26 October 2012: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, today announces its results for the third quarter and the first nine months 2012, for the period ended 30 September 2012.26 Oct 2012
-
Presentation of the third quarter 2012 report23 Oct 2012
-
Photocure to Exit Allumera BusinessOslo, Norway, 1 October 2012: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces today that it has made the strategic decision to exit its Allumera® cosmetic dermatology business in the US.01 Oct 2012
-
Results second quarter and first half 2012Oslo, Norway, 24 August 2012: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, today announces its results for the second quarter and the first half year 2012, for the period ended 30 June 2012.24 Aug 2012
-
Photocure ASA – Presents second quarter and first half year 2012 report on Friday August 24th.Kjetil Hestdal, President & CEO will present the report at 15:00 CET22 Aug 2012
-
Interview: Simplifying Existing Procedure Eases Market Penetration for PhotocurePresident and CEO Kjetil Hestdal discusses the company's photodynamic technology harnessed in Hexvix® and Allumera®. Hexvix®, branded as Cysview® in the U.S., aids in cystoscopy procedures for bladder cancer.06 Jul 2012
-
Photocure strengthens the management teamAnnounces appointment of Chief Finance Officer05 Jul 2012
